


Discover our *in vitro* B cell depletion models

From blood cancers to autoimmune disease, B cell depletion is reshaping what's possible in immuno-oncology and immunology.

At RoukenBio, our human whole peripheral blood mononuclear cell (PBMC) and bone marrow mononuclear cell (BMMC) B cell depletion models evaluate your therapeutic in the presence of naturally occurring immune cell populations and physiological effector-to-target ratios. This enables assessment of mechanisms such as T cell-mediated cytotoxicity, ADCC and ADCP, delivering physiologically relevant, translationally meaningful data to confidently drive your candidate forward.

B cell depletion: from blood to bone marrow

- Our integrated assays link target cell depletion to functional immune outcomes
- Suitable for both healthy and disease state cells
- Applicable across a range of modalities including:
 - Monoclonal antibodies
 - T cell engagers
 - Antibody drug complexes
 - CAR-Ts



Direct experience working with donor material across a range of autoimmune diseases, including RA, SLE, Sjögren's disease, immune thrombocytopenia and autoimmune haemolytic anaemia

One Assay - Three dimensions of performance

Whole PBMC TDCC links reliable depletion data with subset resolution and T cell activation.

Quantify total depletion



Independent CD19 and CD20 readouts support robust measurement while reducing the impact of target-epitope masking.

Resolve disease-relevant subsets




Measure differential depletion across phenotypically distinct B cell populations, including naïve and switched memory cells.

Confirm effector engagement




Track CD4+ and CD8+ T cell activation and cytokine secretion via flow cytometry and ELISA.



TOTAL B CELL DEPLETION



SUBSET-SPECIFIC DEPLETION



T CELL ACTIVATION



Additional Offerings

Purified Populations

Evaluate therapeutic activity against purified B cell subsets, providing greater resolution of depletion efficiency and sensitivity across distinct B cell populations.

Target Expressing Cell Lines

Assess depletion against defined target-expressing cell lines, providing a reproducible system to characterise activity across different target expression profiles.

Single-Arm Activation

Assess activation in the absence of B cells, enabling characterisation of target-independent activity and providing a more complete understanding of therapeutic function.

Download our B cell depletion slide deck

Explore how this model could support your programme.



 **RoukenBio** - The CRO redefined

Backed by our brilliant minds, we have turned the traditional CRO model on its head, by fostering a collaborative and personalised approach. Our mission is simple:

Solve problems. Deliver quality data. Propel your drug discovery breakthroughs.

United by a passion to make sense of complexities and overcome challenges, we apply our specialised knowledge to big-picture thinking. We will explore every option to deliver over and above for your project.

We are thought leaders with a deep understanding of immunology, bioassays, molecular biology and a track record of groundbreaking discoveries and novel cell-based tools.